Valvular & structural heart diseaseSecondary analysis
Balloon- Versus Self-Expanding Transcatheter Valves for Failed Small Surgical Aortic Bioprostheses: 3-Year Results of the LYTEN Trial
- prespecified secondary analysis of the LYTEN randomized trial
Authors' conclusion
In patients undergoing valve-in-valve TAVR for failed small aortic bioprostheses, SEV demonstrated a superior valve hemodynamic performance at 3-year follow-up, with similar clinical outcomes and functional improvement compared with BEV.
Study context
- Population
- Patients with a failed small (≤23 mm) surgical valve undergoing valve-in-valve transcatheter aortic valve replacement (TAVR)patients underwent TAVR · balloon-expandable valves (BEV) 46 · self-expanding valves (SEV) 52
- Participants
- Ninety-eight patients
- Comparison
- BEV vs SEV
- BEVn = 46
- SEVn = 52
Primary result
As reported in the abstract
Intended valve performance · 3 years
Further findings
Mean gradient · 3 years
Indexed effective orifice area · 3 years
Moderate aortic regurgitation · 3 years
Composite of death, stroke, or heart failure-related hospitalization · 3 years
Mortality · 3 years
- Mean gradient: P =0.002
- Indexed effective orifice area: P =0.002
- Moderate aortic regurgitation: P =0.582
- Composite of death, stroke, or heart failure-related hospitalization: P =0.489
- Mortality: P =0.375
Functional status and quality of life · 3 years
- improved similarly in both groups
Original publication
Balloon- Versus Self-Expanding Transcatheter Valves for Failed Small Surgical Aortic Bioprostheses: 3-Year Results of the LYTEN Trial. Circ Cardiovasc Interv. Published 2 February 2026. doi:10.1161/circinterventions.125.016255
Summarised from the published abstract; every number is checked against it